Source - GNW

Bagsværd, Denmark, 14 June 2017 - Novo Nordisk today announced the submission of a Type II Variation application to the European Medicines Agency (EMA) for including data in the label for Tresiba® (insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba® compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes.

Further information

Media:  
Katrine Sperling +45 4442 6718 [email protected]
Ken Inchausti (US) +1 609 786 8316 [email protected]
    
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 [email protected]
Hanna Ögren +45 3079 8519 [email protected]
Anders Mikkelsen +45 3079 4461 [email protected]
Kasper Veje (US) +1 609 235 8567 [email protected]

Company announcement No 44/2017





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire